427 related articles for article (PubMed ID: 18539480)
1. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Bigner DD
Semin Immunol; 2008 Oct; 20(5):267-75. PubMed ID: 18539480
[TBL] [Abstract][Full Text] [Related]
2. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
Heimberger AB; Sampson JH
Expert Opin Biol Ther; 2009 Aug; 9(8):1087-98. PubMed ID: 19591631
[TBL] [Abstract][Full Text] [Related]
3. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
4. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA
Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919
[TBL] [Abstract][Full Text] [Related]
5. EGFRvIII-targeted vaccination therapy of malignant glioma.
Choi BD; Archer GE; Mitchell DA; Heimberger AB; McLendon RE; Bigner DD; Sampson JH
Brain Pathol; 2009 Oct; 19(4):713-23. PubMed ID: 19744042
[TBL] [Abstract][Full Text] [Related]
6. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Choi BD; Kuan CT; Cai M; Archer GE; Mitchell DA; Gedeon PC; Sanchez-Perez L; Pastan I; Bigner DD; Sampson JH
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):270-5. PubMed ID: 23248284
[TBL] [Abstract][Full Text] [Related]
7. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
Wikstrand CJ; Cole VR; Crotty LE; Sampson JH; Bigner DD
Cancer Immunol Immunother; 2002 Feb; 50(12):639-52. PubMed ID: 11862416
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
9. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
[No Abstract] [Full Text] [Related]
10. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Herndon JE; Lally-Goss D; McGehee-Norman S; Paolino A; Reardon DA; Friedman AH; Friedman HS; Bigner DD
Mol Cancer Ther; 2009 Oct; 8(10):2773-9. PubMed ID: 19825799
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.
Heimberger AB; Archer GE; Crotty LE; McLendon RE; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Neurosurgery; 2002 Jan; 50(1):158-64; discussion 164-6. PubMed ID: 11844246
[TBL] [Abstract][Full Text] [Related]
12. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
[TBL] [Abstract][Full Text] [Related]
13. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
Sampson JH; Choi BD; Sanchez-Perez L; Suryadevara CM; Snyder DJ; Flores CT; Schmittling RJ; Nair SK; Reap EA; Norberg PK; Herndon JE; Kuan CT; Morgan RA; Rosenberg SA; Johnson LA
Clin Cancer Res; 2014 Feb; 20(4):972-84. PubMed ID: 24352643
[TBL] [Abstract][Full Text] [Related]
14. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.
Choi BD; Suryadevara CM; Gedeon PC; Herndon JE; Sanchez-Perez L; Bigner DD; Sampson JH
J Clin Neurosci; 2014 Jan; 21(1):189-90. PubMed ID: 24054399
[TBL] [Abstract][Full Text] [Related]
15. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
Del Vecchio CA; Li G; Wong AJ
Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
[TBL] [Abstract][Full Text] [Related]
16. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
[TBL] [Abstract][Full Text] [Related]
17. A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice.
Wang X; Lu XL; Zhao HY; Zhang FC; Jiang XB
Cancer Immunol Immunother; 2013 Jul; 62(7):1261-72. PubMed ID: 23640602
[TBL] [Abstract][Full Text] [Related]
18. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas.
Li G; Mitra S; Wong AJ
Neurosurg Clin N Am; 2010 Jan; 21(1):87-93. PubMed ID: 19944969
[TBL] [Abstract][Full Text] [Related]
19. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
[TBL] [Abstract][Full Text] [Related]
20. Antibody-based immunotherapy for malignant glioma.
Gedeon PC; Riccione KA; Fecci PE; Sampson JH
Semin Oncol; 2014 Aug; 41(4):496-510. PubMed ID: 25173142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
